|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RBPs affected by excitotoxicity included TAR DNA-binding protein 43 (TDP-43) and, most robustly, fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS).
|
31092554 |
2019 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identify a bromodomain and extraterminal (BET) protein-cooperated FUS-DDIT3 function in myxoid LPS and a BET protein-dependent core transcriptional regulatory circuitry consisting of FOSL2, MYC, and RUNX1 in de-differentiated LPS.
|
30903020 |
2019 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
|
26865464 |
2016 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyotrophic lateral sclerosis (ALS) is caused by mutations in a number of genes, including the gene encoding the RNA/DNA-binding protein translocated in liposarcoma or fused in sarcoma (TLS/FUS or FUS).
|
26251528 |
2015 |
|
liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MMP-2-mRNA and protein expression correlated significantly with FUS-CHOP positivity in 46 resected patient liposarcoma tissues.
|
24285420 |
2014 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is a multifunctional DNA-/RNA-binding protein that is involved in a variety of cellular functions including transcription, protein translation, RNA splicing, and transport.
|
25289647 |
2014 |
|
liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in fused in sarcoma and/or translocated in liposarcoma (FUS, TLS or FUS) are linked to familial cases of amyotrophic lateral sclerosis (ALS).
|
25444610 |
2014 |
|
liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation.
|
23836491 |
2013 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress.
|
24090136 |
2013 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myxoid round cell liposarcoma (MRCLS) is a common liposarcoma subtype characterized by a translocation that results in the fusion protein TLS:CHOP as well as by mixed adipocytic histopathology.
|
22293175 |
2012 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A real time PCR based approach for the quantitative detection of FUS-CHOP fusion transcripts in human liposarcoma.
|
22543255 |
2012 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in superoxide dismutase 1 (SOD1), TAR DNA-binding protein (TARDBP, also known as TDP43) and fused in sarcoma (FUS, also known as translocated in liposarcoma (TLS)) account for approximately 30% of classic familial ALS.
|
21857683 |
2011 |
|
liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that FUS-CHOP expression in a p53-deficient background is sufficient to initiate liposarcoma in mouse but not in hASCs, suggesting the need of additional cooperating mutations in hASCs.
|
21732477 |
2011 |
|
liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We thus investigated whether the loss of one FUS allele by translocation in liposarcoma may be followed by mutations in either the remaining FUS allele or the paralogous EWSR1.
|
21344536 |
2011 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein.
|
20541619 |
2010 |
|
liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differential expression of TCN1 (transcobalamin I), IFI44 (Interferon-induced protein 44), HMGB2 (high-mobility group box 2) and FUS [Fusion (involved in t(12;16) in malignant liposarcoma)] among other genes were further confirmed by western-blot and/or real-time polymerase chain reaction.
|
20042637 |
2010 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In light of these findings we also analyze the potential significance of a novel association between ALS, altered autophagy, and mutations of nuclear proteins such as TAR-DNA-Binding Protein 43 and fused in sarcoma/translated in liposarcoma.
|
20406184 |
2010 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Analysis of CHOP rearrangement in pleomorphic liposarcomas using fluorescence in situ hybridization.
|
19037998 |
2009 |
|
liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, eIF4E was also strongly upregulated in normal adipose tissue of FUS-DDIT3 transgenic mice, suggesting that overexpression of eIF4E may be a primary event in the initiation of liposarcomas.
|
18596980 |
2008 |
|
liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to study the usefulness of trabectedin in the treatment of patients with myxoid liposarcomas, a subtype of liposarcoma that is associated with specific chromosomal translocations t(12;16)(q13;p11) or t(12;22)(q13;q12) that result in the formation of DDIT3-FUS or DDIT3-EWSR1 fusion proteins.
|
17586092 |
2007 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, this study provides genetic evidence that the presence of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposarcoma development and establishes that PPARgamma inactivation is required for liposarcoma development.
|
17468515 |
2007 |
|
liposarcoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Taken together, this study provides genetic evidence that the presence of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposarcoma development and establishes that PPARgamma inactivation is required for liposarcoma development.
|
17468515 |
2007 |
|
liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cytogenetic hallmark of myxoid type and round cell type liposarcoma consists of reciprocal translocation of t(12;16)(q13;p11) and t(12;22)(q13;q12), which results in fusion of TLS/FUS and CHOP, and EWS and CHOP, respectively.
|
16884691 |
2006 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The identification of FUS-CHOP transcript is potentially useful in the diagnosis and research of oral liposarcomas.
|
16414544 |
2006 |
|
liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, because the fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype when expressed in a primitive sarcoma cell line, MLS/RCLS may develop from cell types other than preadipocytes.
|
16651630 |
2006 |